Interim 2019/2020 Influenza Vaccine Effectiveness in Japan from October 2019 to January 2020
-
- Tsuzuki Shinya
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Faculty of Medicine and Health Sciences, University of Antwerp, Belgium
-
- Ishikane Masahiro
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
-
- Matsunaga Nobuaki
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan
-
- Morioka Shinichiro
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
-
- Yu Jiefu
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
-
- Inagaki Takeshi
- General Internal Medicine, National Center for Global Health and Medicine, Japan Department of Emergency Medicine and Critical Care, National Center for Global Health and Medicine, Japan
-
- Yamamoto Makiko
- Department of Emergency Medicine and Critical Care, National Center for Global Health and Medicine, Japan
-
- Ohmagari Norio
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
Search this article
Description
<p>Herein, we report the interim vaccine effectiveness (VE) of a quadrivalent inactivated influenza vaccine, during the 2019/2020 influenza season, in Japan. We conducted a retrospective observational cohort study of 381 patients aged ≥15 years, who were enrolled with influenza like illnesses and examined via the rapid influenza diagnostic test, at the Ambulatory Care unit of the National Center for Global Health and Medicine in Tokyo, Japan, from the beginning of October 2019 to the end of January 2020. VE was estimated using a test-negative design. VE was calculated as (1 – odds ratio) × 100%, comparing influenza A test positivity between vaccinated and unvaccinated patients. Of the 381 patients initially screened for inclusion, 314 were enrolled in the study. Of these, 105 were vaccinated, 98 were diagnosed with influenza A, and 5 were diagnosed with influenza B. Overall VE against influenza A was 27.6% (95% confidence interval [CI], ‒21.1 to +57.4), and in patients aged ≥65 years, it was 47.3% (95% CI, ‒76.0 to +86.0). This indicates that the influenza vaccination offered continued protection during the 2019/2020 influenza season, but a detailed analysis of more cases with a careful consideration of methodology is necessary to estimate VE more precisely.</p>
Journal
-
- Japanese Journal of Infectious Diseases
-
Japanese Journal of Infectious Diseases 74 (3), 175-179, 2021-05-31
National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee
- Tweet
Details 詳細情報について
-
- CRID
- 1390006662425309952
-
- NII Article ID
- 130008041983
-
- NII Book ID
- AA1132885X
-
- ISSN
- 18842836
- 13446304
-
- NDL BIB ID
- 031491120
-
- PubMed
- 32999182
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed